Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on June 15, 2018. The report covers a specific corporate event occurring on the same date regarding the company's clinical trial progress.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical development milestone rather than financial performance.
Material Changes
The material change reported is the completion of the first dose cohort for PCM-075, a highly-selective Polo-like Kinase 1 (PLK1) Inhibitor. This milestone was achieved in a Phase 1b/2 clinical trial evaluating the drug in combination with decitabine for patients with Acute Myeloid Leukemia (AML).
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the inherent nature of clinical trials. The primary disclosure is the successful progression of the PCM-075 trial as detailed in the attached press release (Exhibit 99.1).
Investor Verification Checklist
- Verify the full details of the PCM-075 Phase 1b/2 trial results in the attached press release (Exhibit 99.1).
- Confirm the safety and tolerability data for the combination of PCM-075 and decitabine in AML patients.
- Check subsequent filings for the next steps in the clinical trial timeline.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial status.